Next Article in Journal
In Vitro, In Vivo, and In Silico Models of Lymphangiogenesis in Solid Malignancies
Previous Article in Journal
The Role of Artificial Intelligence in Early Cancer Diagnosis
 
 
Editorial

Molecular Pathology of Pancreatic Cancer

by 1,2,†
1
Pancreatic Cancer Research, Institute of Pathology, University of Bern, CH-3008 Bern, Switzerland
2
Pancreatobiliary and GI-Pathology, Pathology Institute Enge, CH-8005 Zurich, Switzerland
www.pancreascarcinoma.ch.
Cancers 2022, 14(6), 1523; https://doi.org/10.3390/cancers14061523
Received: 10 March 2022 / Accepted: 14 March 2022 / Published: 16 March 2022
(This article belongs to the Special Issue Molecular Pathology of Pancreatic Cancer)
Note: In lieu of an abstract, this is an excerpt from the first page.

Pancreatic ductal adenocarcinoma (PDAC) is a biologically aggressive malignancy showing a remarkable resistance to existing therapies and is often diagnosed at an advanced stage, leaving only about 15–20% of patients with an option for surgical resection [...] View Full-Text
Show Figures

Figure 1

MDPI and ACS Style

Karamitopoulou, E. Molecular Pathology of Pancreatic Cancer. Cancers 2022, 14, 1523. https://doi.org/10.3390/cancers14061523

AMA Style

Karamitopoulou E. Molecular Pathology of Pancreatic Cancer. Cancers. 2022; 14(6):1523. https://doi.org/10.3390/cancers14061523

Chicago/Turabian Style

Karamitopoulou, Eva. 2022. "Molecular Pathology of Pancreatic Cancer" Cancers 14, no. 6: 1523. https://doi.org/10.3390/cancers14061523

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop